Recently, Soilu-Hanninen et al. [11] reported a 1 year, double blind, placebo controlled, randomized study in 66 MS patients with vitamin D3 as an add-on treatment to IFN-β. The gene discussed is IFNB1; the disease is myeloid sarcoma.